ID: ALA4103562

Max Phase: Preclinical

Molecular Formula: C25H21ClF3N5O2S2

Molecular Weight: 580.06

Molecule Type: Small molecule

Representations

Canonical SMILES:  CS/C(N)=N\C(=N/S(=O)(=O)c1ccc(C(F)(F)F)cc1)N1CC(c2ccccc2)C(c2ccc(Cl)cc2)=N1

Standard InChI:  InChI=1S/C25H21ClF3N5O2S2/c1-37-23(30)31-24(33-38(35,36)20-13-9-18(10-14-20)25(27,28)29)34-15-21(16-5-3-2-4-6-16)22(32-34)17-7-11-19(26)12-8-17/h2-14,21H,15H2,1H3,(H2,30,31,33)

Standard InChI Key:  FTGCSCGERPAADR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 580.06

Molecular Weight (Monoisotopic): 579.0777

AlogP: 5.58

#Rotatable Bonds: 4

Polar Surface Area: 100.48

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 5.69

CX LogP: 6.15

CX LogD: 6.14

Aromatic Rings: 3

Heavy Atoms: 38

QED Weighted: 0.32

Np Likeness Score: -1.11

References

1. Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, Coffey NJ, Pacher P, Kunos G..  (2017)  Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.,  60  (3): [PMID:28085283] [10.1021/acs.jmedchem.6b01504]

Source

Source(1):

• Scientific Literature